HEC89736
/ Sunshine Lake Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
May 15, 2026
A Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies
(clinicaltrials.gov)
- P1 | N=5 | Terminated | Sponsor: Sunshine Lake Pharma Co., Ltd. | N=80 ➔ 5 | Active, not recruiting ➔ Terminated; Adjustment to the sponsor's development strategy
Enrollment change • Trial termination • Hematological Malignancies • Oncology
May 06, 2022
A Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies
(clinicaltrials.gov)
- P1 | N=80 | Active, not recruiting | Sponsor: Sunshine Lake Pharma Co., Ltd. | Recruiting ➔ Active, not recruiting
Enrollment closed • Hematological Disorders • Hematological Malignancies • Oncology
April 29, 2021
A Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies
(clinicaltrials.gov)
- P1; N=80; Recruiting; Sponsor: Sunshine Lake Pharma Co., Ltd.
Clinical • New P1 trial • Hematological Disorders • Hematological Malignancies • Oncology
1 to 3
Of
3
Go to page
1